MYDA Advisors LLC Acquires New Position in Benitec Biopharma Inc. (NASDAQ:BNTC)

MYDA Advisors LLC bought a new stake in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 50,000 shares of the biotechnology company's stock, valued at approximately $632,000. MYDA Advisors LLC owned 0.22% of Benitec Biopharma as of its most recent SEC filing.

Separately, Geode Capital Management LLC grew its position in shares of Benitec Biopharma by 31.3% in the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company's stock worth $772,000 after buying an additional 20,012 shares during the period. Hedge funds and other institutional investors own 52.19% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $28.00 price target on shares of Benitec Biopharma in a research report on Monday, March 24th. JMP Securities boosted their price target on Benitec Biopharma from $18.00 to $20.00 and gave the stock a "market outperform" rating in a research report on Thursday, April 10th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $24.71.

Benitec Biopharma Price Performance

NASDAQ BNTC traded down $0.27 during trading hours on Friday, hitting $13.63. The company's stock had a trading volume of 10,029 shares, compared to its average volume of 41,173. The company's 50 day simple moving average is $13.06 and its two-hundred day simple moving average is $11.65. The company has a market cap of $319.64 million, a P/E ratio of -9.03 and a beta of 0.76. Benitec Biopharma Inc. has a 12 month low of $5.74 and a 12 month high of $16.90.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.19. As a group, research analysts predict that Benitec Biopharma Inc. will post -1.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Benitec Biopharma news, Director Suvretta Capital Management, L purchased 900,000 shares of the firm's stock in a transaction on Wednesday, March 26th. The shares were acquired at an average cost of $13.00 per share, for a total transaction of $11,700,000.00. Following the completion of the transaction, the director now owns 8,793,245 shares of the company's stock, valued at approximately $114,312,185. The trade was a 11.40 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.30% of the company's stock.

Benitec Biopharma Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.